Tobira Therapeutics, a Manalapan, NJ-based developer of therapies to treat HIV, has named Andrew Hindman president and CEO, according to a news release. Hindman was most recently senior v.p. of development at Nodality, a San Francisco-based developer of molecular diagnostic tools. Tobira is in phase 2b testing of Cenicriviroc, a drug that targets two co-receptors—one required for HIV infection and the other for a number of metabolic and cardiovascular diseases. “With the right team, the right compound and the right strategy, Tobira is well-poised to realize Cenicriviroc’s potential to become an integral component of future once-daily HIV treatment regimens,” Hindman said in the release.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
